Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Maruho Co., Ltd.

Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth

The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen. 

Japan Business Strategies

Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases

Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases. 

Financing StartUps and SMEs

Strong Uptake For Incyte Eczema Cream Despite Formulation Issue

Ahead of pending regulatory decisions on both sides of the Atlantic for Opzelura, Incyte has reported promising progress for the JAK inhibitor in the highly competitive atopic dermatitis market.

Sales & Earnings Launches

Carogra, Xenpozyme Among Japan World-First Approvals

The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.

Japan Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register